Pfizer sells Chinese IP to seal Wyeth deal
01 June 2010
|
Peter Ollier, Hong Kong
US pharmaceutical company Pfizer has sold the Chinese IP rights for a swine flu vaccine to a domestic company to comply with an anti-monopoly review by the Chinese Ministry of Commerce
The world's largest research-based drug maker has sold the Chinese patent rights to Harbin Pharmaceutical Group and will provide the company with technical assistance and training on how to use the vaccine for up to three years.
"This is the first time in China that this kind of commitment has been made, but it happens quite often in the US and the EU," said Adrian Emch, a consultant of Hogan Lovells in Beijing.
Pfizer announced on January 26 last year that it would buy US rival Wyeth for $68 billion in cash and stock. On June 9 the company submitted its merger filing with the Anti-Monopoly Bureau of China's...
Only subscribers have complete access to Managing IP,
log in or
subscribe now.
Alternatively take a
free trial, giving you seven days access to Managing IP and regular newsletters for the international IP community, and US and Canadian practitioners specifically.
Subscribe Now
This article is available to subscribers. Please click subscribe to read the rest of the article.
Subscribe
Take a free trial
Please take a free 48-hour trial to gain limited access. Some articles and surveys may be excluded.
Take a free trial